The estimated Net Worth of Kyriazi Theo Melas is at least $977 ezer dollars as of 16 February 2023. Mr. Melas owns over 8,750 units of Kaleido Biosciences Inc stock worth over $2 and over the last 21 years he sold KLDO stock worth over $508,755. In addition, he makes $468,031 as Independent Director at Kaleido Biosciences Inc.
Sign up
Mr. Kyriazi KLDO stock SEC Form 4 insiders trading
Theo has made over 8 trades of the Kaleido Biosciences Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of KLDO stock worth $1 on 16 February 2023.
The largest trade he's ever made was exercising 212,675 units of Kaleido Biosciences Inc stock on 10 June 2004 worth over $3,530,405. On average, Theo trades about 20,463 units every 340 days since 2003. As of 16 February 2023 he still owns at least 15,350 units of Kaleido Biosciences Inc stock.
You can see the complete history of Mr. Melas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Theo Melas-Kyriazi biography
Theo Melas-Kyriazi serves as Independent Director of the Company. Mr. Melas-Kyriazi has served as Chief Financial Officer of Levitronix Technologies Inc. and its predecessor companies since 2006. Levitronix Technologies Inc. manufactures and sells magnetically-levitated pumps primarily to microelectronics and life sciences customers. Mr. Melas-Kyriazi also serves as an Executive Partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and grows first-in-category life sciences companies, which he joined in April 2019. Mr. Melas-Kyriazi served as a director at Evelo Biosciences, Inc. a role he has held since February 2017. He also served as a director at Valeant Pharmaceuticals International, Inc from 2003 to 2016. From 1986 to 2004, Mr. Melas-Kyriazi served in a variety of management roles at Thermo Fisher Scientific. Mr. Melas-Kyriazi received his M.B.A. from Harvard Business School.
What is the salary of Theo Kyriazi?
As the Independent Director of Kaleido Biosciences Inc, the total compensation of Theo Kyriazi at Kaleido Biosciences Inc is $468,031. There are 5 executives at Kaleido Biosciences Inc getting paid more, with Jerald Korn having the highest compensation of $1,505,420.
How old is Theo Kyriazi?
Theo Kyriazi is 60, he's been the Independent Director of Kaleido Biosciences Inc since 2019. There are 4 older and 12 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.
What's Theo Kyriazi's mailing address?
Kyriazi's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Kaleido Biosciences Inc
Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm és Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.
What does Kaleido Biosciences Inc do?
the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.
What does Kaleido Biosciences Inc's logo look like?
Complete history of Mr. Melas stock trades at Thermo Fisher Scientific, Evelo Biosciences Inc, Kaleido Biosciences Inc és Codiak BioSciences
Kaleido Biosciences Inc executives and stock owners
Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:
-
Jerald Korn,
General Counsel, Corporate Secretary -
Katharine Knobil,
Chief Medical Officer and Head of Research and Development -
William E. Duke Jr.,
Chief Financial Officer -
Daniel L. Menichella B.A., M.B.A.,
Pres, CEO & Director -
Jean Mixer,
Independent Director -
Theo Melas-Kyriazi,
Independent Director -
Michael Bonney,
Chairman of the Board -
Anthony Quinn,
Independent Director -
Grady Burnett,
Independent Director -
Bonnie Bassler,
Independent Director -
Anne Prener,
Independent Director -
William Duke,
Chief Financial Officer -
Daniel Menichella,
President, Chief Executive Officer, Principal Executive Officer -
Dr. Alison Long M.D., Ph.D.,
Chief Medical Officer -
Dr. Mark A. Wingertzahn Ph.D.,
Sr. VP of R&D and Head of Devel. -
Susan Stewart J.D.,
Chief Regulatory Affairs  Advisor -
Dr. Johan Van Hylckama Vlieg Ph.D.,
Chief Scientific Officer -
Kimberly Hocknell,
Sr. VP of Technical Operations -
Jerald Korn J.D.,
COO, Gen. Counsel & Corp. Sec. -
Dr. Geoffrey von Maltzahn Ph.D.,
Co-Founder & Director -
Hylckama Vlieg Johan Van,
Chief Scientific Officer -
Ventures Fund Iv General Pa...,
-
Joshua T Brumm,
See Remarks -
Alison Frances Lawton,
See Remarks -
Maltzahn Geoffrey Von,
Director -
Ventures Fund V General Par...,
-
Ventures Fund Iv General Pa...,
-
Ventures Fund Iv General Pa...,
-
Alison S Long,
Chief Medical Officer